Senti Bio anticipates that subsequent events and developments may cause Senti Bio's assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The ...

Senti Bio released a KOL segment discussing leukemia research and its lead program, SENTI-202, featuring Drs. Strickland and Rajangam. Senti Biosciences, Inc. has released a Virtual Investor KOL ...

SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...

Senti Biosciences Inc SNTI announced a new strategic collaboration with Celest Therapeutics (Shanghai) Co Ltd, a China-based biotechnology company, for the clinical development of SENTI-301A to treat ...

SENTI-202 currently being evaluated in Phase 1 study for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia SOUTH SAN FRANCISCO, Calif., May 22, 2025 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Senti Biosciences, Inc., the gene circuit company focused on outsmarting complex diseases with intelligent medicines, today announced that Jose Iglesias, ...

A ready-made version of a cutting-edge cancer immunotherapy can effectively defeat blood cancers, a new study says. Researchers have prepared an off-the-shelf version of CAR immune cell treatment that ...

$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia SOUTH SAN FRANCISCO, Calif., July 01, ...

Building circuits isn’t common in biotech labs, particularly labs developing cell-based therapies for cancer. Tim Lu, who studied computer science and electrical engineering as an undergraduate before ...